Quantcast

Latest Tapentadol Stories

2014-10-22 08:31:01

Results indicate Zalviso controlled moderate-to-severe acute pain following abdominal surgery better than placebo, with similar side effect profile REDWOOD CITY, Calif., Oct. 22, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) today announced that results from the IAP310 study have been published in Regional Anesthesia and Pain Medicine (RAPM), a peer-reviewed journal with broad, multidisciplinary readership. IAP310 was a randomized, placebo-controlled, Phase 3...

2014-09-16 12:31:25

SAN FRANCISCO, Sept. 16, 2014 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) reported today that partner AstraZeneca today announced that the US Food and Drug Administration (FDA) approved MOVANTIK((TM)) (naloxegol) tablets as the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC), in adult patients with chronic, non-cancer pain. Opioids play an important role in chronic pain relief...

2014-06-26 08:27:08

Top-line results anticipated by end-of-year RALEIGH, N.C., June 26, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it has completed enrollment of all patients required for its initial Phase 3 study of Clonidine Topical Gel for the treatment of painful diabetic neuropathy (PDN). http://photos.prnewswire.com/prnvar/20110217/CL49801LOGO The Phase 3 trial is a multicenter, randomized, double-blind, placebo-controlled study to determine the...

2014-06-12 12:28:55

LONDON, June 12, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Moderate Pain - Pipeline Review, H1 2014 http://www.reportbuyer.com/pharma_healthcare/treatments/moderate_pain_pipeline_review_h1_2013.html Moderate Pain - Pipeline Review, H1 2014 Summary Global Markets Direct's, 'Moderate Pain - Pipeline Review, H1 2014', provides an overview of the Moderate Pain's therapeutic pipeline. This report provides comprehensive information on the therapeutic...

2014-04-24 16:28:58

ORMD-0801 Oral Insulin Appeared Safe and Well-tolerated. No Hypoglycemic Events or Treatment Related Adverse Events Observed JERUSALEM, April 24, 2014 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today detailed results from its previously completed Phase IIa trial investigating ORMD-0801, its orally ingestible insulin capsule, in type 2...

2014-04-03 08:28:55

Product has fast track designation by FDA RALEIGH, N.C., April 3, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced today the enrollment of the first patient in the RHAPSODY Study, a Phase 3 clinical trial of Clonidine Topical Gel for the treatment of painful diabetic neuropathy. The Phase 3 trial is a multicenter, randomized, double blind, placebo controlled study to determine the efficacy and safety of Clonidine Topical Gel in the treatment...

2014-02-11 20:21:26

DUBLIN, February 11, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/tgtpbg/drug_solubility) has announced the addition of the "Concise Analysis of Drug Solubility Technology: Spray Drying, Extrusion, and SCF" [http://www.researchandmarkets.com/research/tgtpbg/drug_solubility ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) As drug suppliers re-examine their business models to adjust...

2014-02-05 04:20:49

MELBOURNE, Australia, February 5, 2014 /PRNewswire/ -- - Phase 2 trial met its primary endpoint, reduced pain in postherpetic neuralgia (PHN) versus placebo - Significant patient response to EMA401 treatment and drop in pain intensity compared with placebo, meeting a key secondary endpoint - First published demonstration of the therapeutic potential of angiotensin II type 2 (AT2)receptor antagonists - EMA401...

2014-01-16 16:23:41

DUBLIN, January 16, 2014 /PRNewswire/ -- Dublin - Research and Markets ( http://www.researchandmarkets.com/research/sqmftt/pain_therapeutics) has announced the addition of a new report "Pain Therapeutics - Drugs, Markets and Companies" [http://www.researchandmarkets.com/research/sqmftt/pain_therapeutics ] to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) This report describes the latest concepts of pathomechanisms of pain as a basis...


Word of the Day
negawatt
  • A unit of saved energy.
Coined by Amory Lovins, chairman of the Rocky Mountain Institute as a contraction of negative watt on the model of similar compounds like megawatt.